Abstract: A plant based cheese is made of a protein such as cashew protein, liquid low saturated fat vegetable oil, cultures and modified food starches. The ingredients are combined to form an emulsion, which is heated and held at a selected temperature for a selected time such that starches gelatinize. Shear is applied to the emulsion. The emulsion is liquid at the selected temperature but when cooled, the emulsion becomes solid. In its solid state, when it is heated, the product melts, closely resembling certain dairy cheeses. The liquid oil has relatively low saturated fat.

Abstract: An end effector device for use with a scanning electron microscope includes a body defining a shaft extending along a longitudinal axis between a distal end and a proximal end. The proximal end features a bulbous portion, while the distal end has a first aperture aligned with the longitudinal axis, designed to receive a stem of a scanning electron microscope sample holder. The proximal end has a second aperture aligned with the longitudinal axis to receive an extension rod. The body also has a clip aperture, defined as a blind bore extending partially into the shaft, substantially orthogonal to the longitudinal axis. A clip is positioned within the clip aperture, held in place with a pin traversing through a pin aperture, allowing the clip to transition between a stem-engaging and a release configuration. A spring is positioned between the clip and the body to bias the clip to the stem-engaging configuration. The body is 3D printed, starting at the planar proximal end defined by the bulbous portion.

Abstract: A data encoding method includes identifying within an image at least a foveal zone and a peripheral zone, the foveal zone of the image being estimated to coincide with the fovea of a user's eye when viewed by the user, encoding for transmission the different zones of the image at different qualities, the encoding quality for the foveal zone being higher than for the peripheral zone, and transmitting the encoded image to a remote viewing device; meanwhile, a data decoding method includes receiving an encoded image, different portions of the encoded image having been encoded at different qualities according to whether they are in at least a foveal zone and a peripheral zone, the foveal zone of the image being estimated to coincide with the fovea of a user's eye when viewed by the user, and the encoding quality for the foveal zone being higher than for the peripheral zone, decoding the portions of the image according to a respective decoding scheme corresponding to the respective encoding of each portion of the

Abstract: Dosages and regimens based on the discovery of unexpectedly high and sustained exposure of INX-315 in humans in need thereof which results in increased efficacy per dose and minimizes adverse events during treatment, including by minimizing the ratio of Cmax to Cmin, resulting in a decrease in an initial drug spike after administration.

Abstract: An advantageous isolated morphic form of trilaciclib which is 2?-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1,5]pyrrolo[2,3-d]pyrimidin]-6?-one, for example in the form of a dihydrochloride salt or a dihydrochloride, dihydrate.

Abstract: An advantageous isolated morphic form of trilaciclib which is 2?-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1,5]pyrrolo[2,3-d]pyrimidin]-6?-one, for example in the form of a dihydrochloride salt or a dihydrochloride, dihydrate.

Abstract: An advantageous isolated morphic form of trilaciclib which is 2?-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1,5]pyrrolo[2,3-d]pyrimidin]-6?-one, for example in the form of a dihydrochloride salt or a dihydrochloride, dihydrate.

Abstract: A fuel composition comprising as an additive the reaction product of a polycarboxylic acid having no more than 5 carbon atoms per carboxylic acid group, or an anhydride thereof and an alcohol having at least 5 carbon atoms.

Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

Abstract: The present invention relates to the prevention and/or treatment of retinal disorders, such as cone dystrophies, cone-rod dystrophies, in particular Achromatopsia.

Abstract: This invention provides an unexpectedly stable, highly crystalline form of the di-HCl salt of for advantageous therapeutic pharmaceutical efficacy and dosage form stability.

Abstract: The invention relates to the use of gene therapy vectors to improve vision by introducing into healthy rod photoreceptor cells of a patient suffering from cone photoreceptor dysfunction and/or degeneration a nucleic acid encoding a gene product that is light-sensitive and/or that modulates endogenous light-sensitive signalling in a photoreceptor cell, such that the range of light intensities to which the rod photoreceptor responds is extended and/or the speed at which the rod photoreceptor responds to light is increased

Abstract: An advantageous isolated morphic form of trilaciclib which is 2?-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1,5]pyrrolo[2,3-d]pyrimidin]-6?-one, for example in the form of a dihydrochloride salt or a dihydrochloride, dihydrate.

Abstract: An advantageous isolated morphic form of trilaciclib which is 2?-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1,5]pyrrolo[2,3-d]pyrimidin]-6?-one, for example in the form of a dihydrochloride salt or a dihydrochloride, dihydrate.

Abstract: An advantageous isolated morphic form of trilaciclib which is 2?-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1,5]pyrrolo[2,3-d]pyrimidin]-6?-one, for example in the form of a dihydrochloride salt or a dihydrochloride, dihydrate.

Abstract: A hybrid filter assembly for an aquatic application is provided in the form of a first filtration stage, a second filtration stage in fluid communication with the first filtration stage, a valve system in fluid communication with the second filtration stage, and a controller. The first filtration stage includes a granular media, and the second filtration stage includes a first membrane filtration module and a second membrane filtration module. The valve system is designed to selectively control fluid flow within the second filtration stage. The controller, which is in communication with the valve system, is designed to direct actuation of the valve system to fluidly isolate the first membrane filtration module from the second membrane filtration module.

Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

Abstract: A hybrid filter assembly for an aquatic application is provided in the form of a vessel, a first filtration stage, a second filtration stage, a bypass assembly, and a controller. The vessel includes a first port which receives fluid from the aquatic application. The first filtration stage and the second filtration stage are retained in the vessel. The first filtration stage is designed to filter particles imparted with a first size, while the second filtration stage is designed to filter particles imparted with a second size. The bypass assembly is in fluid communication with a second port the vessel. The controller is in communication with the bypass assembly, and the controller actuates the bypass assembly to alter an operational state of the hybrid filter assembly.

Abstract: A method of operating a filtration system including a hybrid filter assembly is provided. The method includes the steps of providing a pump that is in fluid communication with a pool or a spa, providing a hybrid filter assembly including a filtration module, providing a chemical cleaning system including a container configured to retain a chemical cleaning agent in which the container is in fluid communication with the hybrid filter assembly, and providing a controller in communication with the hybrid filter assembly and the chemical cleaning system. The method also includes the steps of determining via the controller an operational efficiency of the filtration module at a predetermined interval of time and initiating via the controller a chemical cleaning mode to clean the hybrid filter assembly.

Abstract: A system for an aquatic application is provided in the form of a pump, a filtration system, a container, and a controller. The container is arranged to be in fluid communication with the filtration system and retains a chemical cleaning agent. The valve is positioned to be in fluid communication with the container and the filtration system. The controller is in communication with the valve. The controller is designed to determine a first permeability value associated with the filtration system at a first time period and initiates a cleaning procedure by providing the chemical cleaning agent to the filtration system when the first permeability value is below a permeability threshold value.